A Randomized Double Blind Study of Adjuvant Immunotherapy with Nivolumab vs Placebo After Complete Resection of Stage IIb/C Melanoma (CA209-76K)
A Randomized Double Blind Study of Adjuvant Immunotherapy with Nivolumab vs Placebo After Complete Resection of Stage IIb/C Melanoma (CA209-76K)
Trial Category:
Melanoma
Phase
III
Contact(s)
Location(s)
Nebraska Cancer Specialists, Omaha, NE
